Cargando…

Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults

To determine if ivacaftor (Kalydeco) influences non-CF human CFTR function in vivo, we measured CFTR-dependent (C-sweat) and CFTR-independent (M-sweat) rates from multiple identified sweat glands in 8 non-CF adults. The two types of sweating were stimulated sequentially with intradermal injections o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jeeyeon, Farahmand, Miesha, Dunn, Colleen, Milla, Carlos E., Horii, Rina I., Thomas, Ewart A. C., Moss, Richard B., Wine, Jeffrey J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214959/ https://www.ncbi.nlm.nih.gov/pubmed/30389955 http://dx.doi.org/10.1038/s41598-018-34308-8

Ejemplares similares

Evaporimeter and Bubble-Imaging Measures of Sweat Gland Secretion Rates
por: Kim, Jeeyeon, et al.
Publicado: (2016)

Variation in CFTR-dependent ‘β-sweating’ among healthy adults
por: DeRose, Lesje, et al.
Publicado: (2022)

A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking Ivacaftor
por: Char, Jessica E., et al.
Publicado: (2014)

The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements
por: Char, Jessica E., et al.
Publicado: (2017)

In Vivo Readout of CFTR Function: Ratiometric Measurement of CFTR-Dependent Secretion by Individual, Identifiable Human Sweat Glands
por: Wine, Jeffrey J., et al.
Publicado: (2013)

Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation
por: Rowe, Steven M., et al.
Publicado: (2013)

Structure of ABCB1/P-Glycoprotein in the Presence of the CFTR Potentiator Ivacaftor
por: Barbieri, Alessandro, et al.
Publicado: (2021)

Ivacaftor Therapy in CF Patients: Single Center Experience
por: Mondal, Pritish, et al.
Publicado: (2014)

Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1)
por: Lingam, Swathi, et al.
Publicado: (2017)

The use of ivacaftor in CFTR mutations resulting in residual functioning protein
por: Guigui, S., et al.
Publicado: (2016)

Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
por: Ooi, Chee Y., et al.
Publicado: (2018)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023)

Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
por: Shaughnessy, Ciaran A., et al.
Publicado: (2021)

Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations
por: Csanády, László, et al.
Publicado: (2019)

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes
por: Lefferts, Juliet W., et al.
Publicado: (2023)

Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
por: Shaughnessy, Ciaran A., et al.
Publicado: (2021)

CF Fungal Disease in the Age of CFTR Modulators
por: Bercusson, Amelia, et al.
Publicado: (2021)

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry
por: Sutharsan, Sivagurunathan, et al.
Publicado: (2023)

PKA Mediates Constitutive Activation of CFTR in Human Sweat Duct
por: Reddy, M. M., et al.
Publicado: (2009)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
por: Bacalhau, Mafalda, et al.
Publicado: (2023)

New therapies for people with CF in the CFTR modulator world
por: Wainwright, Claire E
Publicado: (2020)

Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages
por: Aridgides, Daniel S., et al.
Publicado: (2023)

Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation
por: Bernarde, Cédric, et al.
Publicado: (2015)

Ivacaftor in Omani children with cystic fibrosis caused by p.Ser549Arg CFTR mutation
por: Al Oraimi, Sumaya, et al.
Publicado: (2022)

CFTR potentiator ivacaftor protects against noise-induced hair cell loss by increasing Nrf2 and reducing oxidative stress
por: Wu, Fan, et al.
Publicado: (2023)

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018)

Correction: In vivo readout of CFTR function: Ratiometric Measurement of CFTR-Dependent Secretion by Individual, Identifiable Human Sweat Glands
Publicado: (2014)

Multicenter Intestinal Current Measurements in Rectal Biopsies from CF and Non-CF Subjects to Monitor CFTR Function
por: Clancy, John P., et al.
Publicado: (2013)

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
por: Laselva, Onofrio, et al.
Publicado: (2021)

Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation
por: Kristensen, Maartje I., et al.
Publicado: (2021)

Fertility, Pregnancy and Lactation Considerations for Women with CF in the CFTR Modulator Era
por: Jain, Raksha, et al.
Publicado: (2021)

Defective Fluid Secretion from Submucosal Glands of Nasal Turbinates from CFTR(-/-) and CFTR(ΔF508/ΔF508) Pigs
por: Cho, Hyung-Ju, et al.
Publicado: (2011)

From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis
por: Gramegna, Andrea, et al.
Publicado: (2020)

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
por: Veit, Guido, et al.
Publicado: (2020)

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations
por: Hardisty, Gareth R., et al.
Publicado: (2021)

CFTR bearing variant p.Phe312del exhibits function inconsistent with phenotype and negligible response to ivacaftor
por: Raraigh, Karen S., et al.
Publicado: (2022)

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
por: Mainz, Jochen G., et al.
Publicado: (2022)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

IMAGE-BASED β-ADRENERGIC SWEAT RATE ASSAY CAPTURES MINIMAL CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) FUNCTION
por: Salinas, Danieli Barino, et al.
Publicado: (2019)

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score
por: Mainz, Jochen G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qd0o3s9vsspl1sv0hjirh9747u